Valuation: Altimmune, Inc.

Market Cap 572M 494M 464M 422M 794M 54.68B 807M 5.44B 2.13B 27.38B 2.15B 2.1B 91B P/E 2026 *
-4.96x
P/E 2027 * -4.37x
Enterprise Value 131M 113M 107M 96.98M 182M 12.56B 185M 1.25B 489M 6.29B 493M 483M 20.91B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
1 day+2.08%
1 week-4.55%
Current month+3.52%
1 month-1.34%
3 months+3.16%
6 months-35.10%
Current year-18.56%
1 week 2.84
Extreme 2.84
3.2
1 month 2.75
Extreme 2.75
3.31
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Chairman 78 01/01/2018
Director/Board Member 74 01/08/2004
Director/Board Member 58 01/09/2003
Date Insider Type Main position Quantity % Market Cap.
13/08/26 Buy

Chief Executive Officer

15,000 0.0077%
31/07/26 Free

Chief Financial Officer

1,753 0.0009%
31/07/26 Free

Chief Technology Officer

875 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%-4.55%-19.01%+4.63% 572M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.11%+1.30%+45.58%+185.51% 26.43B
Weighted average by Cap. -1.08%+0.54%+50.08%+164.65%

Financials

2026 *2027 *
Net sales - -
Net income -102M -88.24M -82.92M -75.41M -142M -9.77B -144M -972M -380M -4.89B -384M -375M -16.26B -127M -110M -103M -93.95M -177M -12.17B -180M -1.21B -473M -6.1B -478M -468M -20.26B
Net Debt -440M -380M -358M -325M -611M -42.12B -621M -4.19B -1.64B -21.09B -1.65B -1.62B -70.1B -332M -286M -269M -245M -460M -31.72B -468M -3.15B -1.23B -15.88B -1.25B -1.22B -52.78B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
14/08/26 $2.940 +2.08% 3,073,969
13/08/26 $2.880 -1.71% 4,108,985
12/08/26 $2.930 -2.33% 6,045,805
11/08/26 $3.000 -1.64% 3,634,639
10/08/26 $3.050 -0.97% 5,260,453
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.940USD
Average target price
17.22USD
Spread / Average Target
+485.79%

Quarterly revenue - Rate of surprise